학술논문

Paranasal sinusitis at the initiation of chemotherapy is a risk factor for invasive fungal disease in children and adolescents with cancer
Original Article
Document Type
Academic Journal
Source
Supportive Care in Cancer. October 2021, Vol. 29 Issue 10, p5847, 6 p.
Subject
Diseases
Risk factors
Diseases -- Risk factors
Cancer -- Risk factors
Septic shock -- Risk factors
Cancer research
Micafungin
Chemotherapy
Meropenem
Oncology, Experimental
Cancer -- Risk factors -- Chemotherapy -- Research
Language
English
ISSN
0941-4355
Abstract
Author(s): Kenji Kishimoto [sup.1], Ryoji Kobayashi [sup.1], Daiki Hori [sup.1], Satoru Matsushima [sup.1], Masato Yanagi [sup.1], Hirozumi Sano [sup.1], Daisuke Suzuki [sup.1], Kunihiko Kobayashi [sup.1] Author Affiliations: (1) grid.415262.6, 0000 [...]
Background The impact of paranasal sinusitis on the clinical outcome of patients with cancer remains unknown. The aim of this study was to determine whether paranasal sinusitis at the initiation of chemotherapy (SAI) affects the development of infectious complications in children and adolescents with cancer. Methods A retrospective cohort analysis of patients aged 0-20 years with cancer who received chemotherapy was performed. SAI was defined as the presence of a fluid level or mucosal swelling or total opacity on sinus computed tomography examination before the initiation of chemotherapy. The primary outcome measures were the incidence of bacteremia, septic shock, and invasive fungal disease (IFD, including proven, probable, and possible cases). Results SAI was observed in 57 (44%) of 130 enrolled patients. There were no significant differences in age, sex, and disease distribution between the patients with SAI (SAI group) and those without (non-SAI group). There was no significant difference in the 1-year cumulative incidence of bacteremia or septic shock after treatment initiation between the two groups (bacteremia, SAI group 33% vs. non-SAI group 35%, P = 0.53; septic shock, SAI group 4% vs. non-SAI group 4%, P = 0.87). The 1-year cumulative incidence of IFD was higher in the SAI group than in the non-SAI group (22% vs. 6%, P = 0.012). Cumulative incidence analysis after inverse probability of treatment weighting adjustment showed that the SAI group was more likely to develop IFD (HR: 3.5, 95% CI: 1.1-11.2, P = 0.033). Conclusions Our findings suggest that patients with SAI may be at higher risk for IFD during chemotherapy.